Donald Trump Preparing Major FDA Shake-Up as Makary Faces Removal

The administration of US President Donald Trump attracts new political attention after speculations surfaced that Food and Drug Administration (FDA) Commissioner Marty Makary could be ousted shortly. According to sources familiar with the situation, the White House has already discussed plans to replace the FDA chief after months of tension within the agency.

According to various US media sources, administration officials feel changes to the FDA are required following internal debates over drug approvals, vaccine restrictions, food regulations, and vaping policy. According to reports, Trump personally endorsed the notion of replacing Makary, but no official announcement has been made as of yet.

Makary, a surgeon and public health expert at Johns Hopkins University, was appointed FDA commissioner in 2025 after winning Senate approval. During the COVID-19 pandemic, he received national notoriety for his media appearances and public health commentary. During his tenure at the FDA, Makary championed various measures aimed at expediting medicine reviews and eliminating food additives in consumer items.

Internal Conflicts and Policy Disputes Raise Pressure Inside FDA

According to reports, conflicts inside the administration grew as Makary made decisions that upset various political and industry groupings. Some pharmaceutical corporations allegedly chastised the FDA’s new review method, while conservative groups questioned the agency’s handling of abortion-related drugs and flavored vaping goods.

According to sources, several senior FDA officials left the agency during Makary’s tenure, causing uncertainty at a time when the US healthcare system is coping with prescription shortages, vaccine policy conflicts, and escalating food safety concerns.

The White House has not publicly stated if Makary will resign. However, sources indicate that officials are already exploring both temporary and permanent successors for the FDA’s top position. Former FDA leaders Stephen Hahn and Brett Giroir, as well as FDA Deputy Commissioner Kyle Diamantas, are reportedly being considered.

Health Agency Changes Could Affect US Medical Policies

Makary’s likely departure is seen as part of broader changes underway at major US health agencies under the Trump administration. In recent months, various departments involved in public health and medical regulation have undergone leadership changes and policy restructures.

Healthcare professionals think that another abrupt leadership change at the FDA might undermine public trust and cause delays in critical medical decisions such as approvals for drugs, vaccines, and food safety measures. Others suggest that the administration seeks greater control over agencies involved in public health programs ahead of potential political conflicts in Washington.

Despite mounting allegations, Trump openly disputed that a final decision had been reached. However, political watchers believe the case demonstrates ongoing conflicts inside America’s top health organizations, as disagreements over science, regulation, and public health remain highly sensitive subjects in the country.

Donald Trump Signals Possible Shift in FDA Direction

According to reports, Donald Trump is plotting a big leadership shake-up at the US Food and Drug Administration, with FDA chief Marty Makary apparently under consideration for removal. According to people familiar with the situation, internal debates over policy decisions and regulatory priorities may have contributed to the rising stress. While no official declaration has been made, the situation has already ignited political debate in Washington.